Table 2.
Cancer type | Method | Mycoplasma species | Detection rate (%)∗ | Study population∗ | Country | Year | Reference |
---|---|---|---|---|---|---|---|
Prostate cancer | RT-PCR | M. hominis | 15 | 125 | Russia | 2011 | [82] |
ELISA | M. hominis | 3 | 118 | ||||
PCR | 7 Mycoplasma spp. | 35.4 | 31 | Turkey | 2013 | [83] | |
RT-PCR | M. genitalium | 9.56 | 115 | Australia | 2014 | [84] | |
U. urealyticum | 0.86 | ||||||
U. parvum | 0 | ||||||
PCR | U. urealyticum | 1.61 | 62 | Iran | 2015 | [85] | |
M. genitalium | 0 | ||||||
PCR | M. genitalium | 40 | 45 | Japan | 2019 | [86] | |
M. hyorhinis | 0 | ||||||
U. urealyticum | 0 | ||||||
RT-PCR | M. hominis | 13.11 | 61 | Iran | 2020 | [87] | |
PCR and sequencing | U. parvum | 20 | 50 | KSA | 2020 | [88] | |
U. urealyticum | 16 | ||||||
| |||||||
Gastric cancer | PCR | 12 Mycoplasma spp. | 48 | 23 | Japan | 1995 | [89] |
Southern blot | M. hyorhinis | 15 | 27 | ||||
Immunohistochemistry PCR |
M. hyorhinis | 56 | 90 | China | 2001 | [90] | |
Immunohistochemistry | M. hyorhinis | 54.1 | 98 | China | 2002 | [91] | |
Immunohistochemistry | M. hyorhinis | 45.9 | 61 | China | 2006 | [92] | |
M. fermentans | — | ||||||
Nested PCR | M. hyorhinis | 63.9 | |||||
M. fermentans | 31.14 | ||||||
Culture | M. hyorhinis | 8.19 | |||||
M. fermentans | 3.27 | ||||||
M. hyorhinis + M. fermentans coinfection | 1.63 | ||||||
| |||||||
Ovarian cancer | Combined PCR-ELISA | 15 Mycoplasma spp. | 59.3 | 27 | USA | 1996 | [93] |
Combined PCR-ELISA | 15 Mycoplasma spp. | 13 | 29 | Korea | 1998 | [94] | |
Nested PCR | 12 Mycoplasma spp. | 13 | 46 | USA | 2001 | [95] | |
Sequencing | M. arginini | 5 | |||||
M. salivarium | 1 | ||||||
Lipid-associated membrane protein-enzyme immunoassay (LAMP-EIA) | M. genitalium | 11.76 | 68 | Sweden | 2011 | [96] | |
| |||||||
Cervical cancer | Combined PCR-ELISA | 15 Mycoplasma spp. | 33.3 | 9 | USA | 1998 | [97] |
Nested PCR | M. penetrans | 45.45 | 55 | China | 2007 | [98] | |
Metagenomic sequencing | Ureaplasma spp. M. hominis M. genitalium |
51.4 34 2.3 |
134 | USA Tanzania |
2020 | [99] | |
| |||||||
Colon cancer | Immunohistochemistry PCR |
Mycoplasma spp. | 55.1 | 58 | China | 2001 | [90] |
Esophagus cancer | 50.9 | 53 | |||||
Breast cancer | 39.7 | 63 | |||||
Brain cancer | 41 | 91 | |||||
| |||||||
Non-Hodgkin's lymphoma | PCR | M. fermentans | 10.9 | 265 | UK | 2001 | [100] |
Renal cancer | Nested PCR | 15 Mycoplasma spp. | 82 | 33 | Turkey | 2005 | [101] |
Nested PCR | Mycoplasma spp. | 81.8 | 95 | China | 2008 | [102] | |
Bladder cancer | Culture and nested PCR | M. penetrans | 41.8 | 55 | China | 2009 | [103] |
Laryngeal cancer | Culture and PCR | M. salivarium | — | 1 case | USA | 2012 | [104] |
Tongue cancer | TaqMan PCR | M. salivarium | — | 1 case | Germany | 2014 | [105] |
Oropharynx cancer | PCR | M. hominis | — | 1 case | France | 2020 | [106] |
| |||||||
Lung cancer | Immunohistochemistry PCR |
Mycoplasma spp. | 52.6 | 59 | China | 2001 | [107] |
PCR | Mycoplasma spp. | 22.2 | 27 | Turkey | 2004 | [108] | |
ELISA | M. pneumoniae | — | 1 case | Canada | 2017 | [109] |
∗Detection rate in control populations is not reported here. Only patients with confirmed cancer diagnosis are considered. (—) sign, data not mentioned.